NovaBay Pharmaceuticals (NBY) PT Lowered to $2.50 at Ascendiant Capital
Tweet Send to a Friend
Ascendiant Capital analyst Edward Woo lowered the price target on NovaBay Pharmaceuticals (NYSE: NBY) to $2.50 (from $4.50) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
